DaVita Inc. (DVA) Earnings Call Transcript & Summary
August 5, 2025
Earnings Call Speaker Segments
Nic Eliason
executiveThanks for joining us for this second-quarter conference call, and we're glad you're still following what's happening at our company. I'm Nic Eliason, Group Vice President of Investor Relations, and with me today are Javier Rodriguez, who serves as our CEO, and Joel Ackerman, our CFO. Before we go further, keep in mind that forward-looking statements within the meaning of the federal securities laws may be made during this call. Known and unknown risks and uncertainties apply to each of those statements, and those factors could make actual results differ materially from what the forward statements describe. If you want more detail on those risks and uncertainties, take a look at our second quarter earnings press release along with our SEC filings, which include our most recent annual report on Form 10-K, every subsequent quarterly report on Form 10-Q, and any other later filings we might submit to the SEC. What we say in forward-looking statements rests on information available to us right now, and we neither intend nor take on any duty to update them, except where the law may require it. We also want to remind everyone that some non-GAAP financial measures will be discussed on this call. Our earnings press release furnished to the SEC, which you can also find on our website, contains a reconciliation of those non-GAAP measures to the most comparable GAAP financial measures. At this point I'll hand the call over to Javier Rodriguez.
Javier Rodriguez
executiveThank you, Nic, and I appreciate everyone being on the call. We're happy to share that this was another solid quarter, one in which our dedication to delivering exceptional patient care and creating a great experience for our caregivers kept driving our results. Our financial commitments were met, underpinned by strong clinical performance and disciplined execution throughout our businesses. In my remarks today, I'll walk through the highlights of our second quarter results, provide my perspective on key policy developments, talk about how device innovation is evolving, and close with our outlook for the remainder of the year. As always, let's start with a clinical highlight. Normally I spotlight one specific clinical achievement, but today I'd like to step back and offer some historical perspective as I reflect on the exciting opportunities that lie ahead for DaVita and the kidney care community. During the 2 decades before the COVID-19 pandemic, remarkable clinical progress was made by the kidney care community. Technological and pharmaceutical advances, together with greater adoption of standardized care, produced better outcomes and major declines in mortality rates. COVID disrupted not just operations but also the health acuity of our patients. Still, from today's vantage point, I feel optimistic about the future, and I believe a new wave of clinical innovation is beginning, one with exciting potential for the patients we serve. New breakthroughs—everything from sophisticated IT platforms to AI’s game-changing capabilities—are set to let us tailor care in ways we’ve never seen before. As more people start using newer kinds of medicines, such as GLP-1s and SGLT2s, and as next-generation devices that do a better job clearing middle-sized molecules arrive, there’s a chance to prolong life and make recovery from dialysis easier than it used to be. Armed with these resources, those of us in kidney care are ready to push clinical results higher once more. We can bring death rates down, make life better for the people we treat, and provide superior care. Naturally, getting there requires both time and money, yet we’re pressing ahead confidently, anchored in our vision of relentlessly chasing a healthier tomorrow. Now I'd like to turn to how we did in Q2. Our adjusted operating income and adjusted EPS both landed a bit above what we had projected. You can see in these numbers two key themes we called out three months ago, and they're still very much in play. Theme one: we can hit the 3%-7% adjusted operating income growth we promised even without yet delivering the volume growth we're aiming for. Q2 showed this clearly — patient care costs performed strongly enough to outweigh the cyber-related drag on revenue per treatment and volume. Even so, getting volume moving again stays a top priority, and we still expect to get back to 2% annual treatment growth eventually. As we see this recovery taking form, we're also pursuing additional opportunities to hit the operating income and EPS goals we've set for the long term. Our belief that we can generate enough cost savings to offset the weak volumes we're seeing right now rests on a pair of factors: the expense discipline we've shown across the company, and the significant investments we've made in systems and IT going back several years. The business's ability to withstand environmental and unexpected challenges — that's the second theme I want to highlight. Roughly 3 months have passed since the cyber incident we discussed last quarter first occurred, so let me walk through our recovery work in more detail, along with the financial impact involved. On the operational side, patient care has continued without interruption. Two broad buckets capture the financial effects we've absorbed. The first bucket covers discrete costs tied to the incident — things like outside consultants, technology costs, legal costs, and so forth. Those amounted to roughly $13 million during the second quarter and are left out of second quarter adjusted operating income, treated as non-GAAP expenses. The second bucket, which matters more, concerns how treatment volume and revenue per treatment were affected by fewer patient admissions, higher rates of missed treatment, and reduced anticipated yield on claims for treatment in this quarter, among other factors. Beyond the lingering effect of a lower census resulting from lost admit opportunities, we think the cyber event's influence is mostly in the past, and any continuing effect on adjusted results will be minimal. Joel is going to give you additional detail on how these dynamics are playing out. I'll shift now to a handful of policy updates. During the prior quarter, we shared an update covering several policy changes, among them tariffs, Medicaid cuts, and qualified health plans. Congress has since passed additional legislation, and every one of these subjects is still in flux, yet our projections of how these items will affect DaVita have not changed since last quarter. Also, late in June, CMS released the 2026 ESRD proposed rule. The roughly 2% bump to the dialysis rate matched what we had anticipated, but as has been true in recent years, it keeps coming in below the real inflation that dialysis providers face. Keep in mind that an incremental update to the Medicare rate will come through the final rule later this year. One last item before turning to guidance. There's considerable conversation and momentum within the industry around new technology arriving in the United States aimed at improving clinical outcomes via better clearance of middle sized molecules during dialysis. High-volume hemodiafiltration (HDF) is one such technology. We really support clinical innovation that can improve how patients do and how well they live, and these technologies have a lot of promise; when it comes to the current situation, we've got several work streams going. That covers monitoring both current and upcoming clinical trials to assess how effective different solutions are — not only HDF machines, but also sophisticated dialyzers, which could produce similar clinical results. As more clinical data comes in, we'll watch what doctors favor, and finally, we're looking at what each innovation means operationally, factoring in clinical outcomes as well as health economics. There's a great deal to feel positive about, even though there's still a lot we need to understand. Our commitment to being at the forefront of clinical innovation hasn't wavered at all, and we're genuinely enthusiastic about what it means for delivering better care to the patients who depend on us. Turning to the balance of the year, we're holding firm on our guidance for adjusted operating income between $2.01 billion and $2.16 billion, along with adjusted earnings per share in the range of $10.20 to $11.30, even with the drag from the cyber incident. On top of that, our confidence remains intact that we can achieve adjusted operating income and adjusted EPS growth in line with our long-term guidance. At this point, I'll pass it to Joel, who will walk through our financial results and outlook in greater detail.
Joel Ackerman
executiveThanks, Javier. For the second quarter, adjusted operating income came to $551 million, adjusted earnings per share were $2.95, and free cash flow totaled $157 million. I'll walk through each piece of our results, starting with U.S. dialysis. On treatment volume: daily U.S. treatments fell 1.1% compared with the second quarter of 2024, roughly 50 basis points under what we had expected for the quarter. That softness stemmed mostly from a mistreatment rate that came in higher than anticipated. Our view is that the cyber outage was the main cause, though separating the effects of cyber from other underlying trends is hard to do. Given the elevated mistreatment rate in Q2, we've raised our assumptions for mistreatment rate across the rest of the year, which brings down our full year treatment volume outlook. We now expect a decline of 75 to 100 basis points year over year, against our prior guide of down 50 basis points. Keep in mind this forecast covers the absolute number of treatments, not treatments per day or non-acquired growth. Turning to revenue per treatment, RPT rose about $4.50 from the first quarter. That usual sequential step up reflects greater patient responsibility for co-pays and deductibles. During Q1, the overall increase fell short of our expectations, mainly because of the cyber incident in April. RPT for the quarter also came in below our expectations due to lower dispensing volumes of binders. With those two dynamics at play, we now expect full year RPT growth near the lower end of our original range of 4.5%-5.5%. Now on to patient care costs, PCCs per treatment were down roughly $3.50 sequentially. Three factors primarily drove this. First, treatment count was higher than in Q1; second, labor productivity improved in our centers; and third, binders. As I noted earlier, binder dispensing volume fell short of our expectations and declined from Q1; we expect the outperformance in patient care costs to persist through the remainder of the year, producing a full year increase of 5%-6% versus 2024, which is better than our original expectations. Let me focus on binders briefly: as I said, both revenue and patient care costs tied to phosphate binders were lower in Q2 than in Q1 because dispensing volumes were lower. We anticipate no net impact from this or from other small changes in our assumptions for the back half of the year. Consequently, our full year adjusted operating income expectation from adding binders to the bundle stays unchanged at approximately $50 million. International adjusted operating income rose $6 million versus the first quarter, mainly because of a one-time benefit. We're excited that the fourth and final Latin American acquisition related to clinics in Brazil closed last week. Integrated Kidney Care, or IKC, our value-based care business, posted adjusted operating income of $26 million in the second quarter. IKC got a boost of roughly $40 million in revenue that we had anticipated recording at a later point in the year. That's a timing advantage tied to the second quarter, and it doesn't change anything about what we expect for the full year. Moving on to capital structure — in Q2 we bought back 3.1 million shares, and since the quarter closed we've repurchased another 2.7 million shares. We ended the quarter at a leverage ratio of 3.34 times consolidated EBITDA, which is higher than Q1 but still well inside our target range. Back in May, we issued $1 billion of senior unsecured debt, and in July we repriced our term loan B, which brought the spread down by 25 basis points, and we raised an extra $250 million that went toward paying down part of our term loan A. These moves show our ongoing work to optimize interest rates, maturities, and liquidity, all consistent with our existing capital allocation philosophy. Now let me move to what we expect for full year 2025. As Javier mentioned, we are reiterating the full year adjusted operating income and adjusted earnings per share guidance ranges shown in our press release; we have confidence that we can keep delivering results in line with our 2025 and long-term guidance while caring intensely for our patients and teammates and investing in our future. That wraps up my prepared remarks for today. Operator, please open the call for Q&A.
Andrew Mok
analystHello, and good afternoon. We appreciate all the details regarding guidance. Could you help us understand how patient census and treatments performed after the cyber attack, and what your expectations are for volumes during the back half? You indicated there would not be a continuing effect, yet you also assumed, as I understand it, that higher mistreatment rates would remain through the latter half of the year and adjusted the treatment growth forecast. Perhaps you could just clarify your thinking on this for us. Thank you.
Javier Rodriguez
executiveThank you, Andrew. Javier here. Before Joel begins his explanation, this matters greatly since many factors are at work in treatment volume, and I believe the simpler aspect is this. We can begin at 10,000 ft. The year is unfolding as anticipated, apart from two major items: a severe flu season and the cyber incident. Naturally, that brings into play all the factors you mentioned. At times it is simply easier to begin at a high level prior to delving into specifics. Joel, could you connect all of those questions? Certainly.
Joel Ackerman
executiveAndrew, I'll do my best to break this down for you. On the call we held three months ago, we said we expected some headwinds when it came to admits stemming from the cyber attack — somewhere in the neighborhood of a few hundred, 500, 600 admits. Things have mostly unfolded the way we thought they would. Those difficulties showed up for several weeks, but since that point, conditions have gotten back to normal. What caught us off guard was a rise in mistreatment rates, and that metric usually moves in a predictable seasonal rhythm: elevated in Q1, lower in Q2 and Q3, then rising again in Q4. Q1 came in above the usual level because of the flu, and our expectation was that it would decline along a standard curve during Q2 — that is not what happened. It stayed high in April and got even worse in May, then fell back in June, though it didn't drop as far as we'd typically anticipate. Mistreatment rates jumped substantially in Q2 on a year-over-year basis, and we tie that to the cyber incident. Because of how that played out, we chose to revise our outlook on mistreatment rate for the back half of the year, whereas before we'd believed it would decline somewhat versus 2024. With the difficulties experienced in the first half of the year from both flu and cyber, we refreshed our assumptions and now assume mistreatment rate will be approximately flat versus last year for the back half of the year. That's the math behind it. Let me remind you, we're discussing a delta of about 0.1%. We're zeroing in on these figures, and the more precise you try to be, the tougher it becomes to truly pinpoint the accuracy; that's just how it works. If you consider the revision to the guide on volume growth, from -50 basis points to — 75 to — 100, it essentially comes down to a higher mistreatment rate, partly in Q2, partly in the back half of the year.
Andrew Mok
analystGreat. Perhaps only a handful of follow-ups regarding phosphate binders. To start, could you tell us what phosphate binders added to RPT and CPT during the quarter? What caused dispensing volumes to come in lower for the quarter? Is that because of fewer treatments, or did the proportion of patients using binders decline? Thanks.
Joel Ackerman
executiveYeah, when it comes to volume, the issue is really a decline in prescription counts. This isn't a mix problem. Our belief is that adherence has fallen short of what we anticipated. Certain patients obtain their binders via other channels beyond DaVita, while others simply turn to over-the-counter options. Volume came in below our expectations with respect to its contribution to RPT and CPT. RPT landed somewhere around the low eights, while CPT was in the high sixes.
Andrew Mok
analystThanks a lot.
Javier Rodriguez
executiveSomething that perhaps you don't know about, or others listening in don't know about, is that with these binders, taking all those pills is quite a burden. And there's a compliance problem tied to it too, since the medication has to be swallowed alongside food. My sense is that some patients slip away because of that situation.
Andrew Mok
analystGreat. Thanks for all the callers.
Javier Rodriguez
executiveThank you.
Pito Chickering
analystHello there, good afternoon, everyone. I suppose I'll begin with the operating income guidance. Could you help connect the dots for us on how you're keeping that guidance unchanged from the prior quarter, given that treatment growth is deteriorating because of mistreatment rates, while revenue per treatment sits at the bottom end of the guidance range? Could you take us through how you're managing to arrive there? Does it come from costs on core kidney? Does it come from improved international or IKC? Just show me the bridge between those two items that moved negatively and how we're, how we're holding operating income guidance steady.
Joel Ackerman
executiveYes, broadly speaking there are two pieces. The largest by a wide margin is cost per treatment, and that mostly reflects a labor dynamic within U.S. dialysis. The second piece relates to international, which came in about $10 million better than planned for the quarter, mostly of a non-recurring nature. I wouldn't annualize that for the second half of the year.
Pito Chickering
analystOkay. With the revised treatment growth of down 7.5 basis points, 100 basis points, the first half of the year was down 70. To reach the midpoint of the range, we're now at down 1.1% in the back half of the year. Could you walk us through incidence, mortality, and transplants? On the mistreatment side, why would those be structural? I understand the flu in Q1 and I understand cybersecurity in Q2. Usually these patients require treatments, or else they die. How can mistreatments turn into a structural headwind?
Joel Ackerman
executiveLet me begin with the mistreatment rate. The mistreatment rate is a figure that fluctuates. It has been elevated since COVID, approximately. It reached a peak at roughly 1% worse than pre-COVID levels in 2022. We had anticipated it would decline from then on, and it did. It was lower in 2023 and 2024; it has risen once more this year. I believe your point is quite reasonable. We're discussing 1/10, perhaps of 1%, perhaps 15 basis points. I think we're fine with simply holding it flat versus 2014. I wouldn't call it a structural problem, just our expectation for the coming couple of quarters. We lowered it somewhat. Let me expand on some of the other dynamics, which really concern admits and mortality. Admits in Q2 were adversely affected by cyber, approximately in line with our expectations. Without that, it would have been a typical admit month, displaying year-over-year growth comparable to what we've observed in most quarters across the last few years. Mortality is still elevated, yet in line with what we saw in Q2 of last year. So the excess mortality we saw in Q1 from flu has declined again, but the overall mortality level is still higher than pre-COVID yet consistent with last year.
Pito Chickering
analystOkay, sure, thanks. I'll get back in line again.
Javier Rodriguez
executiveHey, Pito, something that matters a lot — because occasionally, in trying to keep things simple, folks bring up the CKD population alongside GLP-1s and what happens upstream. In our admits, we're just not observing that. What you're asking about is truly significant, since this interplay between mortality and mistreatment rates genuinely has to be fixed. Like you said, mistreatment rates are somewhat more difficult, but when it comes to mortality, there's a plan with three parts we're pursuing. Reaching that point is going to require time, yet ultimately, as you heard during the opening remarks, the initial step is that we must achieve better clearance of minimal molecules. Second, regarding pharma, more patients need to be placed on GLP-1s — hardly anyone is taking them right now. Third, we're developing a large number of protocols around this to ensure we're able to forecast hospitalization and similar outcomes. Ultimately, we have to bring mortality down.
Pito Chickering
analystGreat. Thanks so much.
Javier Rodriguez
executiveThank you.
A.J. Rice
analystHello everyone. I'd like to inquire about what was said regarding IKC. An additional $40 million during Q2, and it appears you clearly think this represents a pull forward. Could you perhaps share a bit more detail on what took place? What makes you view it as a pull forward rather than possibly a stronger underlying business trend that could persist into the back half of the year?
Joel Ackerman
executiveYes. What gives us confidence that this is a pull forward is that every bit of that revenue ties to 2024 plan years. Here's how it works: when the data arrives and our actuarial and accounting teams become confident that shared savings have truly been earned, that's when we book revenue. We had anticipated reaching that degree of clarity in Q3 and Q4. Some of that clarity came to us sooner in the year. So we booked the revenue earlier, yet we did not book more revenue for the year than anticipated, which explains why this is a matter of timing instead of a net gain for the year.
A.J. Rice
analystAlright, thank you. I might as well ask this too. In your prepared remarks, I believe you mentioned that the cyber attack affected treatment revenue as well. I honestly wasn't — perhaps there's something obvious I'm overlooking, but I didn't understand why that would happen. What's the mechanism at play? Do you expect this to carry into the back half too?
Joel Ackerman
executiveYes. You caught that correctly, A.J., we believe the cyber incident did affect RPT. Our expectation is that it won't carry into the second half of the year. This really breaks down into two pieces. The bigger piece involves how it hit revenue for treatments performed during Q2. Consider that while we were navigating the cyber incident, certain processes became manual, and some things are — other processes either got pushed back or simply aren't getting done. To offer a couple of illustrations, that could be prior authorizations or collecting data on particular elements you'd need for a claim. Since we're operating either by hand or behind schedule, we anticipate that a portion of claims that would typically be approved won't be approved in Q2. That accounts for the larger portion. The smaller portion concerns older claims sitting in the queue that had previously been denied, which we're now trying to get reapproved, whether by gathering information missing from the claim or updating coverage that had changed. As more time passes, collecting on those claims becomes progressively harder. We expect that the cyber incident's effect on systems and other processes will reduce our ultimate yield and essentially drive up bad debt on some of those older claims.
A.J. Rice
analystAlright, understood, many thanks.
Justin Lake
analystThank you, I appreciate that. Joel, I've got a handful of numeric items for you. My recollection is that during the prior quarter's call, you indicated an expectation for revenue per treatment X binders of roughly 3% across the full year. I'm just wondering whether you have a revised figure for that.
Joel Ackerman
executiveYes, at this point we'd put it at approximately 2.25% for the year. The primary factor driving that change is how the cyber incident affected RPT.
Justin Lake
analystAlthough you mentioned this seems limited to just this period, what kind of effect did it have on revenue per treatment for the quarter? Can you give us a figure?
Joel Ackerman
executiveI would say somewhere between $40 million and $50 million.
Justin Lake
analystOkay, so you mentioned the mistreatment rates for the first half of the year, and then I believe you described the second half as being flat compared to the prior year, whereas previously you'd anticipated a decline. Is that accurate?
Joel Ackerman
executiveYes, that's correct.
Justin Lake
analystFor mistreatment rates during the first half, what was the year-over-year growth? I'm looking for a comparison.
Joel Ackerman
executiveQ1 came in slightly worse than Q2, but across the first half of the year it averaged roughly 50 basis points.
Justin Lake
analystAll right, understood. The final item I have: you're providing a figure for treatment growth of a decline of 75 to 100 basis points. That's overall treatment growth. What would that translate to for online, in your view?
Joel Ackerman
executiveU.S. treatment store.
Justin Lake
analystThat isn't correct. That figure covers overall growth in U.S. treatments, correct? I believe most individuals, myself included, look at same store rather than acquired. What would that work out to, in your view?
Joel Ackerman
executiveMy response would be that for same store, non-acquired, the figure comes in at approximately a decline of 50 basis points.
Justin Lake
analystAll right, so excluding acquisitions, you figure performance will improve somewhat compared with the second quarter and resemble the first quarter more closely. The reason is your belief that the cyber attack in the second quarter largely works its way out and finishes. What makes you think it will improve relative to the first half?
Joel Ackerman
executiveThat said, I don't consider NAG a particularly useful figure for modeling. I feel somewhat hesitant about giving you an answer. Keep in mind that growth compared with a year earlier also hinges on how the census trend looked during the previous year. Quarter-over-quarter figures alone aren't something you can depend on. In my view, when it comes to volume growth during the back half of the year, you should anticipate it being worse in Q3, followed by improvement in Q4.
Justin Lake
analystUnderstood. Thank you.
Kevin Fischbeck
analystExcellent, thank you. I'd like to pose one more inquiry regarding the volumes, specifically I suppose the elevated mortality. I value the remarks concerning certain measures you folks intend to take in order to tackle it, yet it remains unclear to me why we face a greater mortality problem in the first place, since I suppose greater mortality suggests a level beyond what existed prior to COVID. The matter you highlighted sort of comes across as newer alternatives that might tackle the matter, as opposed to something regressed and we're going to restore it to its previous level. Rather, it's higher and at present you possess fresh instruments that might reduce it. Simply attempting to determine why mortality, in your estimation, stays persistently higher compared to what it was historically.
Javier Rodriguez
executiveYes, thank you for that inquiry, Kevin. In fact, the actuarial groups are raising that throughout the nation since it isn't merely higher in kidney, but it is higher across every disease state. The theory holds that Covid made an impact, first on merely the postponement of care, and second that coexisting conditions and especially patients who are more acutely ill are perishing more quickly. Those constitute their two theories. No genuine research exists that could demonstrate that as of now. I'm not sure, Joel, whether you've observed anything further you wish to include.
Joel Ackerman
executiveTo start, Kevin, good to have you back. Javier put it well. Our belief is that this is something lingering from COVID, and across the country you can observe it. All-cause mortality figures in the United States have risen, about the same as what DaVita is experiencing; our death rate has gone up. This is a problem nationwide, not one specific to kidneys. What we were attempting to highlight, I think, is that we aren't just sitting around hoping conditions get better, even though that clearly would be beneficial. There are steps both we and others in the industry can take to bring mortality down. This isn't some fresh phenomenon; it truly forms the foundation of volume growth; for close to 20 years before COVID, gains in mortality within the dialysis community came about because of what dialysis providers managed to achieve.
Kevin Fischbeck
analystThat's useful. When we consider those 3 approaches you listed for trying to lessen this, how should the timing work, and when could they start showing up in results?
Javier Rodriguez
executiveSure, it'll happen step by step. Take the improved clearance of metal molecule, whether through high-volume hemodiafiltration or the cutoff dialyzer — those need time before their effects appear. Then with Pharma and GLP-1s, once more, we're X years in and you've got patients using those drugs in the low teens percentage-wise. That's slow too. As for the protocols and systems, those come along gradually and in small increments, yet it's the total collection of efforts that eventually makes a difference. Think in terms of years, not merely 2 quarters.
Kevin Fischbeck
analystAll right. Perhaps this will be our final question. From what I'm hearing, the quarter's narrative seems to be that you clearly faced certain pressures tied to volume and others related to pricing, yet you managed to counterbalance them. Regarding expenses, can these cost programs still be executed once demand returns? Watching the expense management over recent years has been quite remarkable. So does that imply that as soon as demand begins returning, you ought to be expanding at a pace beyond 3%-7%? It appears that if this expense discipline can be sustained, plenty of potential exists once demand settles.
Javier Rodriguez
executiveOperational excellence and discipline are sources of considerable pride for us, and we constantly search for levers capable of driving meaningful change. The brief response is, naturally, nobody can say for certain, since it hinges on volume levels, pickups, and so on. What we're hoping for, and what our approach calls for at present, is that this efficiency will persist. Naturally, with technological progress, we believe we can make that a reality.
Kevin Fischbeck
analystIf volumes are on the rise, then nothing fundamentally stands in the way of managing expenses. There's nothing that's, like, plainly obvious. Okay, fine, that's great. Appreciate it.
Javier Rodriguez
executiveThanks.
Ryan Langston
analystThank you, and good evening. Perhaps I can add a bit more to what Kevin asked about, I suppose, patient care cost. Are there any details about what is kind of fueling that result? I suppose, you know, it seems like you anticipate this continuing for the remainder of the year. Assuming that holds true, is there actually any basis for us not to anticipate it extending into the following year?
Javier Rodriguez
executiveThe primary factor, as Joel mentioned, is productivity. If you were to dig deeper, since as you're aware, productivity contains many variables, you would find that our teammates are remaining with us longer, so our retention has improved somewhat, and our training expenses have declined somewhat because we've gotten better at placing individuals into their roles efficiently and faster.
Ryan Langston
analystUnderstood. And finally, regarding that cyber incident, is there any effect at all when it comes to spending over the longer term? What sort of expectations around hardware, software, whatever else you may need to put money into simply to reduce the odds of something like this occurring once more. Thanks.
Javier Rodriguez
executiveThis is a marginal cost. When all is said and done, those cyber criminals are pretty sophisticated, and they never stop reinventing themselves. Corporations and the industry must keep innovating as well; we have made certain investments that we consider appropriate and prudent, but nothing I would describe as material.
Javier Rodriguez
executiveYes, if you don't mind. Ryan, have you finished?
Ryan Langston
analystYeah, that's all from me, thanks. Okay, thanks.
Lisa Clive
analystHello. I've got a question about the newer technologies out there in the marketplace, especially with this emphasis on clearing bigger molecules. Baxter's Theranova Dialyzer has been available in the U.S. for a number of years now. Clearly, FMC is stepping up its HDF rollout for Theranova next year, and I believe for HDF as well, since you operate clinics in Europe too. To what extent have you adopted these technologies in your own clinics so far? And I'm wondering, how will you actually go about gathering the clinical evidence, essentially running what I'd assume are clinical trials? How long do you figure it will actually take before you have a sense of the impact these new technologies could deliver?
Javier Rodriguez
executiveYeah, let me break that down and see whether I manage to address everything you asked. First, we have experience with both HDF and the mineral molecule dialyzers. We work with various brands, so I won't go into which brand of dialyzer we use. Beliefs differ from country to country. Where HDF is present, sometimes nearly the whole country has it, and sometimes you see just 20%. Clinical practice dynamics play a role, reimbursement dynamics play a role, and other factors too. As you're aware, the CONVINCE study produced some quite encouraging mortality results. There's a study over in Spain known as the MOTHER Study, and that one is essentially pitting both technologies against each other. Ultimately, our goal is what's best for the patients, and what our physicians and patients are asking for. Naturally, we're following the science, because swapping out a dialyzer is far simpler than replacing your entire fleet of machines, prescriptions, and everything else. In the end, if that's what the doctors prefer or that's the direction the science takes us, then naturally we'll do it. We're monitoring this just as you are, and we're running a couple of studies of our own, and we'll be billing as appropriate.
Lisa Clive
analystTo build on what we discussed regarding phosphate binders, the marketplace contains numerous generics, plus, I believe, a pair of more recent options. Do those involve a reduced burden of pills? One of them, as I understand it, is expected to lose exclusivity before long. In your view, is this primarily an issue of patients sticking with treatment rather than one of expense?
Joel Ackerman
executiveMy answer would lean toward adherence. Between Q1 and Q2, the composition we observed did not shift significantly. Having said that, this is only roughly six months in, meaning we continue to learn. Even so, from an OI perspective, our position for the year strikes us as fairly solid. Each quarter brings a decline in the count of moving pieces. For the remainder of the year, $50 million of OI appears to be a fairly sensible projection.
Lisa Clive
analystGreat, thanks for that.
Javier Rodriguez
executiveThank you, Lisa.
Pito Chickering
analystHello everyone, I appreciate the chance to rejoin the line. Regarding free cash flow, my sense is that it's running at roughly $112 million across the first half of the year, yet the guidance was repeated at $1 billion to $1.25 billion, if I understand correctly. Could you walk us through the path back to that free cash flow figure during the latter six months?
Joel Ackerman
executiveTypically, free cash flow comes in on the lighter side during the opening half of the year. The cyber incident set us back considerably in Q2. Making up ground on cyber is going to be the largest piece. The other item I'd highlight for the second half would be cash taxes, which should come in far stronger compared with the first half.
Pito Chickering
analystAlright, that's helpful. Regarding IKC, there's a significant swing in operating income during 2Q, and it sounds like patient counts are rising once more. Could you share what you're observing there, plus your expectations for IKC across the latter six months of the year? Is this happening because you discharged quite a few patients during the first quarter, or simply — what ought we to anticipate from IKC through the remainder of the year?
Joel Ackerman
executiveAcross the opening six months, IKC came in at approximately break even; our full-year guidance hasn't shifted — think of it as around $20 million-ish; that's the figure, and what you should look for, is — $20 million across the latter half of the year. Normally Q4 ought to outperform Q3, even though the timing pattern for adjusted operating income at IKC tends to swing a lot and is hard to forecast, which is evident given what took place in Q2.
Pito Chickering
analystA few fast ones from me. Where does your MA penetration stand right now? Is pricing pressure still working in your favor? Do you get pricing tailwinds because MA is growing?
Joel Ackerman
executiveOn MA, honestly, there isn't a lot left to highlight; we're basically tracking the market. Nothing significant stands out there.
Pito Chickering
analystAll right, regarding the HIX subsidies that lapse in 2026, is it possible for those individuals to be signed up through the American Kidney Fund prior to their transition into government reimbursement?
Joel Ackerman
executiveThat is definitely one option, yes.
Pito Chickering
analystAll right. This is the second-to-last one for the year, so what did the commercial mix look like in this quarter? Has anything shifted regarding home dialysis?
Joel Ackerman
executiveNot material. Slight. Small fluctuations in each. There's nothing worth highlighting.
Pito Chickering
analystAlright, this is my final question, I swear. Regarding that Berkshire sale disclosed today, was it simply routine — they reach that 45% threshold and that's just how it goes?
Joel Ackerman
executiveYou've got it exactly, Pito. It happened in the ordinary course. It was done in accordance with the standstill agreement between us and them.
Pito Chickering
analystGreat. Thanks so much.
Joel Ackerman
executiveThank you.
Javier Rodriguez
executiveThanks, Michelle. I appreciate everyone taking time out this afternoon. As was emphasized today, our top priority is delivering outstanding care to those we treat. Once our clinical goals are met, the financial results will come along afterward. I'm grateful to each of you for being on this call. Take care.
Operator
operatorThanks. That wraps up the conference call for today. At this point, feel free to disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete DaVita Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to DaVita Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DaVita Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.